-7.2 | | Tmem52 | '21 percent oxygen, 37 degree Celsius, 10 percent serum' vs 'none' | growth condition | RNA sequencing of native and ex vivo cultured murine tail tendon fascicles |
6.9 | | Tmem52 | 'AZD7507; AZD5069 (at same dosage); 100 milligram per kilogram' vs 'none' | compound | RNA-seq to investigate differentially expressed genes in KPC mouse PDAC treated with CSF-1R small molecule inhibitor AZD7507 and/or the CXCR2 small molecule inhibitor AZD5069 |
-6.3 | | Tmem52 | 'neural stem cell' vs 'niche cell' | cell type | Transcription profiling by high throughput sequencing of three populations of primary dentate gyrus cells |
-5.9 | | Tmem52 | '70 week' vs '6 week' in 'none; none; | age, irradiate | Pericyte induced reprogramming of the bone marrow microenvironment drives stem and cancer cell quiescence |
-5.4 | | Tmem52 | '21 percent oxygen, 37 degree Celsius, no serum' vs 'none' | growth condition | RNA sequencing of native and ex vivo cultured murine tail tendon fascicles |
5.3 | | Tmem52 | 'Alb-Cre-ERT2 / Cnot1 flox/flox' vs 'Cnot1 flox/flox' in 'none' | compound, genotype, time | RNA-seq of livers in control and Cnot1 tamoxifen-inducible liver-specific knockout mice |
4.7 | | Tmem52 | 'uterine-specific Tsc2-null' vs 'wild type' in 'oopherectomized' | genotype, treatment | Transcription profiling by high throughput sequencing of uterine-specific Tsc2-null mice |
4.4 | | Tmem52 | 'tamoxifen induction at 2 months, wait 3 months' vs 'no tamoxifen induction' in 'luminal cell of prostate epithelium; Nkx3.1-CreERT2 targeted allele' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
4.1 | | Tmem52 | 'tamoxifen induction at 2 months, wait 3 months' vs 'no tamoxifen induction' in 'basal cell of prostate epithelium; CK5-CreERT2 transgenic line' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
4.1 | | Tmem52 | 'neurosphere in differentiation medium; 12 day' vs 'neurosphere; 0 day' in 'wild type genotype' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
-4 | | Tmem52 | 'carotid body' vs 'adrenal medulla' | organism part | Expression profile of mouse carotid body and adrenal medulla [RNA-Seq] |
3.8 | | Tmem52 | 'tamoxifen induction at 2 months, wait 6 months' vs 'no tamoxifen induction' in 'basal cell of prostate epithelium; CK5-CreERT2 transgenic line' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
3.6 | | Tmem52 | 'induced extraembryonic endoderm stem cell; grown in ES cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
3.5 | | Tmem52 | 'tamoxifen induction at 2 months, wait 1 months' vs 'no tamoxifen induction' in 'luminal cell of prostate epithelium; Nkx3.1-CreERT2 targeted allele' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
3.1 | | Tmem52 | 'neurosphere in differentiation medium; 12 day' vs 'neurosphere; 0 day' in 'Cstb knockout' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
3.1 | | Tmem52 | 'liver-specific Cnot3 knockout' vs 'wild type' | phenotype | Roles of mRNA decay in liver development |
3.1 | | Tmem52 | 'AZD5069; 100 milligram per kilogram' vs 'none' | compound | RNA-seq to investigate differentially expressed genes in KPC mouse PDAC treated with CSF-1R small molecule inhibitor AZD7507 and/or the CXCR2 small molecule inhibitor AZD5069 |
-2.9 | | Tmem52 | 'osteosarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-2.8 | | Tmem52 | 'synovial sarcoma' vs 'normal' | disease | Transcription profiling by array of tumors excised from conditional mouse model of synovial sarcoma compared to skeletal muscle from wild type mice |
2.7 | | Tmem52 | 'hepatocyte-derived proliferative ducts (hepPDs)' vs 'hepatocyte' | cell type | Transcription profiling by high throughput sequencing of hepatocyte-derived progenitors cells in a mouse model of oval cell activation |
-2.4 | | Tmem52 | 'synovial sarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
2.4 | | Tmem52 | 'PTEN null' vs 'wild type genotype' | genotype | RNA seq of prostate gland from WT, PTEN pc -/- and PTEN pc-/-;P53 -/- mice |
2.3 | | Tmem52 | 'LDB1 knock-down' vs 'control shRNA' | RNA interference | Role of LDB1 in the transition from chromatin looping to transcription activation |
-2.2 | | Tmem52 | 'lung carcinoma' vs 'normal' in 'lung cell' | cell type, disease | Transcriptome analysis of isolated stormal cells and tumor epithelial cells in mouse lung cancer by RNA-Seq |
1.8 | | Tmem52 | 'beta(3)-adrenergic agonist Cl316,243' vs 'none' at '10 week' | age, stimulus | RNA-seq of age-associated transcriptome changes in brown adipose tissue |
1.7 | | Tmem52 | 'reduced expression of miR-25' vs 'wild type' | phenotype | Transcription profiling by high throughput sequencing of wild type and miR-25 agomir or antagomir treated mice |
-1.7 | | Tmem52 | 'Stat5b (Stat5abnull/Stat5a-)' vs 'wild type' at 'pregnancy' | genotype, sampling time point | Transcription profiling by high throughput sequencing of mouse wild type and Stat5-mutant mammary tissues at parturition and early pregnancy |
1.7 | | Tmem52 | 'liver-specific Cnot1 knockout' vs 'wild type' | phenotype | Roles of mRNA decay in liver development |
1.6 | | Tmem52 | 'Cnot3 knockout' vs 'wild type' | phenotype | RNA-seq of mouse islets from Ins1-cre driven Cnot3 KO and control islets |
1.6 | | Tmem52 | '12 day' vs '5 day' in 'doxycycline; 200 nanogram per milliliter; neoplasm' | compound, phenotype, time | RNA-seq of doxycycline induced tumor and residual mouse primary mammary epithelial cells grown in 3D cell cultures against non-induced controls |
-1.5 | | Tmem52 | 'human-Mfn2 T111A/S442A-overexpressing (Mfn2AA)' vs 'wild type' in '5 week; left ventricle' | age, genotype, organism part | Transcription profiling by high throughput sequencing of a mitofusin 2 (Mfn2) mutant in mouse |
-1.4 | | Tmem52 | 'artesunate and chloroquine (at same dosage); 30 milligram per kilogram' at '10 day' vs 'none' at '7 day' in 'Plasmodium berghei ANKA' | compound, infect, sampling time point | RNA-seq analysis of anti-malarial drug chemotherapy of murine experimental Cerebral Malaria (ECM) |
-1.4 | | Tmem52 | 'carcinoma' vs 'normal' | disease | Gene expression profile between normal mouse skin and carcinomas arising in the skin of RbF/F;K14creERTM;p107-/- mouse |
-1.4 | | Tmem52 | 'diphtheria toxin; 30 nanogram per gram' vs 'none' | stimulus | RNA-seq of mouse brain tissue repopulating microglia in response to traumatic brain injury |
-1.4 | | Tmem52 | 'inh-alpha/Tag transgenic' vs 'wild type' in 'none' | compound, genotype | Novel genes involved in the pathophysiology of gonadotropin-dependent adrenocortical tumorigenesis in mice. |
1.3 | | Tmem52 | 'nmf205, Gcn2 double mutant' vs 'wild type' | genotype | Transcription profiling by high throughput sequencing in cerebellum of mouse Gcn2 -/-, nmf205-/- and nmf205-/-;Gcn2-/- |
-1.3 | | Tmem52 | 'artesunate and chloroquine (at same dosage); 30 milligram per kilogram' at '14 day' vs 'none' at '7 day' in 'Plasmodium berghei ANKA' | compound, infect, sampling time point | RNA-seq analysis of anti-malarial drug chemotherapy of murine experimental Cerebral Malaria (ECM) |
1.3 | | Tmem52 | 'Aire knockout' vs 'wild type' in 'mTEClo' | genotype, phenotype | Transcription profiling by high throughput sequencing of primary cTEC, mTEClo, and mTEChi harvested from wild type and Aire-deficient mice |
-1.3 | | Tmem52 | 'artesunate and chloroquine (at same dosage); 30 milligram per kilogram' at '30 day' vs 'none' at '7 day' in 'Plasmodium berghei ANKA' | compound, infect, sampling time point | RNA-seq analysis of anti-malarial drug chemotherapy of murine experimental Cerebral Malaria (ECM) |
1.3 | | Tmem52 | 'Plasmodium berghei ANKA' at '7 day' vs 'none' at '0 day' in 'none' | compound, infect, sampling time point | RNA-seq analysis of anti-malarial drug chemotherapy of murine experimental Cerebral Malaria (ECM) |
-1.3 | | Tmem52 | 'transgenic C3(1)-SV40Tag; 20 week' vs 'wild type; 8 week' | age, genotype | Prevention of mammary tumor progression by silencing HoxA1 via intraductal injection of nanoparticle-formulated siRNA |
1.3 | | Tmem52 | 'soticlestat; 30 milligram per kilogram' vs 'none' in 'astrocyte; none' | cell type, compound, disease | RNA-seq profiling of three distinct cell populations in a murine model of epilepsia with and without drug treatment |
1.3 | | Tmem52 | 'Sall1 deficient microglia' vs 'wild type microglia' | genotype, phenotype | RNA sequencing of microglia sorted form tamoxifen treated Sall1CreER/fl and control Sall1fl/fl mice |
1.2 | | Tmem52 | 'adipose tissue specific Trim28 knockout' vs 'wild type genotype' in 'male' | genotype, sex | RNA-seq of gonadal adipose tissue from male and female Trim28-WT and Trim28 adipose specific KO mice |
-1.1 | | Tmem52 | 'tamoxifen; autosomal dominant polycystic kidney disease' vs 'none; normal' | compound, disease, time | Expression profiling experiment on Pkd1-mutant mice and mice induced with nephrotoxin DCVC |
-1.1 | | Tmem52 | 'neoplasm' vs 'normal tissue adjacent to neoplasm' | sampling site | Transcription profiling by array of Apc+/Delta716 mouse intestinal polyps vs normal intestinal mucosa |
1 | | Tmem52 | 'human-Mfn2 T111A/S442A-overexpressing (Mfn2AA)' vs 'wild type' in '3 week; left ventricle' | age, genotype, organism part | Transcription profiling by high throughput sequencing of a mitofusin 2 (Mfn2) mutant in mouse |
-1 | | Tmem52 | 'Het (Q175) knock-in' vs 'wild type' in 'brown adipose tissue' | genotype, organism part | Transcriptome profiling in knock-in mouse models of Huntington's disease [AllelicSeries_6month_TissueSurvey_mRNA] |
-1 | | Tmem52 | 'artesunate and chloroquine (at same dosage); 30 milligram per kilogram' at '30 day' vs 'none' at '6 day' in 'Plasmodium berghei ANKA' | compound, infect, sampling time point | RNA-seq analysis of anti-malarial drug chemotherapy of murine experimental Cerebral Malaria (ECM) |
1 | | Tmem52 | 'metaphase II oocyte' vs 'germinal vesicle oocyte' | cell type | Transcription profiling of mouse in vivo matured MII oocytes and fully in vivo grown germinal vesicle oocytes to identify gene transcripts linked to epigenetic reprogramming |
